[go: up one dir, main page]

ZA200800266B - Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease - Google Patents

Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease

Info

Publication number
ZA200800266B
ZA200800266B ZA200800266A ZA200800266A ZA200800266B ZA 200800266 B ZA200800266 B ZA 200800266B ZA 200800266 A ZA200800266 A ZA 200800266A ZA 200800266 A ZA200800266 A ZA 200800266A ZA 200800266 B ZA200800266 B ZA 200800266B
Authority
ZA
South Africa
Prior art keywords
polymethoxyflavones
tocotrienols
bioavailability
compositions
treatment
Prior art date
Application number
ZA200800266A
Other languages
English (en)
Inventor
Guthrie Najla
Wenderoth Sondra
Original Assignee
Kgk Synergize Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kgk Synergize Inc filed Critical Kgk Synergize Inc
Publication of ZA200800266B publication Critical patent/ZA200800266B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA200800266A 2005-06-28 2006-06-28 Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease ZA200800266B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69472005P 2005-06-28 2005-06-28

Publications (1)

Publication Number Publication Date
ZA200800266B true ZA200800266B (en) 2009-08-26

Family

ID=37596076

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800266A ZA200800266B (en) 2005-06-28 2006-06-28 Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease

Country Status (9)

Country Link
US (1) US20070111953A1 (xx)
EP (1) EP1907007A2 (xx)
JP (1) JP2008546845A (xx)
KR (2) KR20080081807A (xx)
AU (1) AU2006263577B2 (xx)
CA (1) CA2613803A1 (xx)
IL (1) IL188449A0 (xx)
WO (1) WO2007002897A2 (xx)
ZA (1) ZA200800266B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080166418A1 (en) * 2007-01-04 2008-07-10 Sones Scott F Krill oil compositions
WO2009055867A1 (en) * 2007-10-31 2009-05-07 The University Of Sydney Treatment of metabolic disease
JP5596317B2 (ja) * 2009-08-18 2014-09-24 静岡県公立大学法人 心疾患予防治療剤
KR101340675B1 (ko) * 2011-12-05 2013-12-12 대구한의대학교산학협력단 탄제레틴을 포함하는 심혈관계 질환의 예방 또는 치료용 약학 조성물
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
DE202023001978U1 (de) 2023-09-20 2023-09-29 Penta Phi Eg Formulierung umfassend Coenzym Q10 und Kreatin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59137421A (ja) * 1983-01-28 1984-08-07 Naganoken Kooridoufu Kogyo Kyodo Kumiai 生理活性物質の製造法
US5217992A (en) * 1989-10-04 1993-06-08 Bristol-Myers Squibb Company Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders
JPH09255570A (ja) * 1996-03-21 1997-09-30 Fujitsuko Kk 血中脂質濃度を低減させる薬剤及び可食性組成物
US6251400B1 (en) * 1997-09-26 2001-06-26 Kgk Synergize Inc Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols
US20010055627A1 (en) * 1997-09-26 2001-12-27 Najla Guthrie Compositions And Methods For Regulating Lipoproteins And Hypercholesterolemia With Limonoids, Flavonoids And Tocotrienols
US6312703B1 (en) * 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US20020127259A1 (en) * 1998-02-06 2002-09-12 Orthoefer Frand T. Rumen by-pass delivery system
US6987125B1 (en) * 1998-10-06 2006-01-17 The United States Of America As Represented By The Secretary Of Agriculture Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxyflavones
JP2003504327A (ja) * 1999-07-08 2003-02-04 プレンダーガスト、パトリック、ティ. 感染症の治療を目的としたフラボン類、クマリン類および関連化合物の使用
JP4012735B2 (ja) * 2001-10-09 2007-11-21 笑子 金城 シークワーサー果皮精油高含有物の抽出方法及びその粉末
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
JP2005518381A (ja) * 2001-12-19 2005-06-23 ザ キグリー コーポレーション 抹消神経・血管疾患の治療方法
WO2003077904A1 (en) * 2002-03-15 2003-09-25 Nichimo Co., Ltd. Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
DE10217557A1 (de) * 2002-04-19 2003-11-06 Degussa Bioactives Gmbh Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix
DE10217555A1 (de) * 2002-04-19 2004-02-19 Degussa Bioactives Deutschland Gmbh Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix
JP4599604B2 (ja) * 2002-04-19 2010-12-15 カーギル テクスチュアライジング ソリューションズ ドイチュラント ゲゼルシャフト ミット ベシュレクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 生体活性のリン脂質含有成分を含有するマトリックス

Also Published As

Publication number Publication date
AU2006263577B2 (en) 2015-08-06
EP1907007A2 (en) 2008-04-09
KR20080081807A (ko) 2008-09-10
KR20130046451A (ko) 2013-05-07
WO2007002897A2 (en) 2007-01-04
US20070111953A1 (en) 2007-05-17
JP2008546845A (ja) 2008-12-25
WO2007002897A3 (en) 2007-06-07
WO2007002897A8 (en) 2007-04-19
IL188449A0 (en) 2008-04-13
CA2613803A1 (en) 2007-01-04
AU2006263577A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
IL245513A0 (en) Medical preparations containing ingenol-3-angelate
GB0522311D0 (en) Pharmaceutical compositions for the treatment of pain
PL2546253T3 (pl) Podstawione dihydropirazolony do leczenia schorzeń sercowo-naczyniowych i hematologicznych
ZA200802762B (en) Pharmaceutical compositions for the treatment of inner ear disorders
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
ZA200809857B (en) Terphenyl derivatives for treatment of alzheimer's disease
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
IL179931A0 (en) Compositions and methods for treatment of cardiovascular disease
IL188449A0 (en) Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease
PT1828151E (pt) Derivados de malonamida como inibidores de gama-secretase para o tratamento da doença de alzheimer
IL183893A0 (en) Pharmaceutical compositions for the treatment of cellulite
EP1971327A4 (en) PHARMACEUTICAL COMPOSITIONS OF ILAPRAZOLE
IL188831A0 (en) Compositions for reducing the incidence of drug induced arrhythmia
EP1809295A4 (en) NEW EPROSARTAN FORMULATIONS HAVING IMPROVED BIOAVAILABILITY
IL185114A0 (en) Use of vitamin d compounds to treat endometriosis
ZA200710664B (en) Processes for the preparation of docetaxel
IL187855A0 (en) Processes for the preparation of docetaxel
IL177673A0 (en) Benzopyran compound useful for the treatment of arrhythmia
PL2307380T3 (pl) Pochodne N’-nitroksyalkilonikotynamidu do leczenia chorób układu sercowo-naczyniowego
EP1865952A4 (en) COMPOSITIONS CONTAINING HISTAMINES FOR THE TREATMENT OF ALLERGIES
SI1942891T1 (sl) Nova kombinacija zdravil kot antidepresiv
HU0500947D0 (en) Composition for treatment of paradontosis
GB0618309D0 (en) Compositions and methods for the treatment of disease
GB0422501D0 (en) Compositions for the treatment of inflamation
PH32005001263S1 (en) Fixed extender of table form